Abatacept topic
Also known as
- Orencia
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.
Ordinarily, full T cell activation requires 1) binding of the T...
full article at wikipedia
| Technology involved |
| Sales |
| Developed by |
| Brand Names |
- Orencia
| Stage of development |
| Target/Biomolecule of Interest |
| Indication or disease |
| therapeutic molecule |
| Delivery Technology |
| Approval Date |
| Patent Expiration |
This is a user-created view. Freebase has more info on this topic Full view »
This topic belongs in the BioVenturist base Remove from base »
With the exception of Wikipedia summaries and some images the
content on this page is typically distributed under
the Creative Commons
Attribution license or Public Domain.
The original description for this topic was automatically generated from the Wikipedia article "Abatacept" licensed under the GNU Free Documentation License .
Last edited by bioventurist Nov 20, 2008
View topic history »
| Gallery | add |
There are no images for this topic yet.
Recent Discussions about Abatacept
There are no conversations on this topic. Would you like to start one?
Start the Discussion »